Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Markets  >  Synaptogenix, Inc.    SNPX

SYNAPTOGENIX, INC.

(SNPX)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SYNAPTOGENIX, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

04/08/2021 | 10:12pm BST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.



Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan

On April 7, 2021, Synaptogenix, Inc. ("we," "us" and "our") held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, our stockholders approved an amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan (the "Plan"). The Plan was amended to increase the total number of shares of our common stock, par value $0.0001 per share (the "Common Stock"), authorized for issuance thereunder from 1,000,000 shares of Common Stock to an aggregate of 2,500,000 shares of Common Stock.

A detailed summary of the amendment to the Plan is set forth in our Definitive Proxy Statement on Schedule 14A for the Special Meeting filed with the U.S. Securities and Exchange Commission on March 12, 2021 (the "Proxy Statement") under the caption "Proposal No. 2 - Approval of an Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan." The foregoing description of the amendment to the Plan does not purport to be complete and is subject to, and qualified in its entirety by reference to the full text of the amendment to the Plan, which is filed hereto as Exhibit 10.1 and incorporated by reference herein.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Special Meeting, the holders of 9,931,549 shares of our Common Stock, or approximately 70.78% of our outstanding shares of Common Stock, were present at the Special Meeting or represented by proxy and, therefore, a quorum was present. At the Special Meeting, our stockholders considered three proposals, which are described briefly below and in more detail in the Proxy Statement. The final voting results for each proposal are set forth below.

Proposal 1 - Board Authorization to Effect a Reverse Stock Split

Our stockholders voted to authorize our board of directors (the "Board") to effect one reverse stock split of our outstanding shares of Common Stock, at any ratio between 1-for-1.5 and 1-for-20, at such time as our Board shall determine, in its sole discretion, before December 31, 2022.



Shares Voted For   Shares Voted Against   Abstentions
   9,038,788             886,496             6,264



Proposal 2 - Approval of Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan

Our stockholders voted to approve an amendment to our Plan to increase the total number of shares of Common Stock authorized for issuance thereunder from 1,000,000 shares of Common Stock to an aggregate of 2,500,000 shares of Common Stock by the following votes:



Shares Voted For   Shares Voted Against   Abstentions
   7,678,240             314,493            42,674









Proposal 3 - Approval of an Adjournment of the Special Meeting, if Necessary, to Solicit Additional Proxies

Our stockholders voted to approve an adjournment of the Special Meeting, in the event that there were insufficient votes to approve Proposal No. 1 or Proposal No. 2, to allow the Board to solicit additional proxies in favor of Proposal No. 1 or Proposal No. 2 by the following votes:

Shares Voted For Shares Voted Against Abstentions

   9,075,806             818,051            37,691


Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.


The following exhibits are filed as part of this report:



Exhibit
Number     Description
  10.1       Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan.

© Edgar Online, source Glimpses

All news about SYNAPTOGENIX, INC.
04/08SYNAPTOGENIX, INC.  : Change in Directors or Principal Officers, Submission of M..
AQ
04/01SYNAPTOGENIX  : Announces Phase 2b Bryostatin-1 Clinical Trial Update
PR
03/30SYNAPTOGE  : SYNAPTOGENIX, INC. Management's Discussion and Analysis of Financia..
AQ
02/17SYNAPTOGENIX, INC.  : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
02/12SYNAPTOGENIX  : to Participate in the Winter Wonderland - Best Ideas from the Bu..
PR
02/04SYNAPTOGENIX  : Synthetic Bryostatin Available to Expand Neurodegenerative Indic..
PR
01/22SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Unregistered S..
AQ
01/19SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Material Modif..
AQ
2020SYNAPTOGENIX  : Management's Discussion and Analysis of Financial Condition and ..
AQ
2020SYNAPTOGENIX, INC.  : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -12,7 M - -9,23 M
Net cash 2020 5,80 M - 4,21 M
P/E ratio 2020 -0,50x
Yield 2020 -
Capitalization 36,5 M 36,5 M 26,5 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 4
Free-Float -
Chart SYNAPTOGENIX, INC.
Duration : Period :
Synaptogenix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Alan J. Tuchman Chief Executive Officer & Director
Daniel L. Alkon President, Director & Chief Science Officer
Robert Weinstein Chief Financial Officer, Secretary & Treasurer
Joshua Nathaniel Silverman Chairman
William S. Singer Vice Chairman